Call us now : +91 80 28528900, 01, 02


DeQuantoTM Infliximab ( Remicade ) PK ELISA KIT (Catalog # PK1001-ST)


Pack Size : 12 X 8 Strips

QTY : 1

PRICE : Enquire

  • Product Specifications

    The PK (PharmacoKinetics) ELISA Kit is specifically designed to detect the amount/ concentration of the drug Infliximab in human serum/plasma.

    • Sensitivity : 6 ng/ml
    • Very cost effective.
    • Assay Duration : 3.15 -3.30 hrs
    • Assay Range : 6.58-50 ng/ml
    • Assay Matrix : Tested and Validated for Human serum or plasma
    • Specificity : Specifically to anti-TNF drug
    • Interference : No interference observed for Rituximab (Mabthera) in the assay range
    • Note: "Remicade®" is a registered trademark of Janssen Biotech Inc.

    The kit is based on very robust ELISA technique and with very high sensitivity.

  • Product Summary


    Infliximab (Remicade) is a therapeutic chimeric monoclonal antibody against tumor necrosis factor (TNF) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Remicade® is a registered trademark of Janssen Biotech Inc. Infliximab drug inhibits the action of TNF and reduces the inflammation and subsequently improves the patient’s health.

    Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.

    EMA Bio-analytical Method Validation Guidelines and industry-recommended practices for ligand-binding assays were used for validation of this kit. This Infliximab ELISA kit has been developed for specific quantification of Infliximab concentration in human serum or plasma with high sensitivity and reproducibility.

    Assay Principle

    DeQuantoTM Infliximab (Remicade) PK ELISA kit is an ELISA based immunoassay. The Infliximab present in the sample binds to pre coated TNF on polystyrene microtiter plate. Non bound or the excess substances are removed by washing. Horseradish peroxidase (HRP) labeled anti-human IgG Fc? specific antibody is added to the wells which binds to the TNF/Infliximab complex in the wells.

    Following a wash to remove any unbound antibody-enzyme reagent, substrate solution is added to the wells. A color product is formed in proportion to the amount of Infliximab present in the sample or standards. The color development is stopped by addition of a stop solution. The absorbance is measured at 450 nm in a microtiter plate reader. The concentration of Infliximab in a sample can be interpolated from the standard curve.